[{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"a530d193-d51c-4599-96ac-93716c7318aa","acronym":"QUILT-3.067","url":"https://clinicaltrials.gov/study/NCT03387085","created_at":"2021-01-18T16:42:58.165Z","updated_at":"2024-07-02T16:35:35.512Z","phase":"Phase 1/2","brief_title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","source_id_and_acronym":"NCT03387085 - QUILT-3.067","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-09-27"},{"id":"c51c4542-8655-4942-b449-a1d17ae733cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03384316","created_at":"2021-01-18T16:42:00.383Z","updated_at":"2024-07-02T16:36:41.287Z","phase":"Phase 1","brief_title":"Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer","source_id_and_acronym":"NCT03384316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETBX-011 • ETBX-051 • ETBX-061"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 05/22/2018","primary_completion_date":" 05/22/2018","study_txt":" Completion: 08/24/2020","study_completion_date":" 08/24/2020","last_update_posted":"2020-09-09"}]